Most ICI-induced colitis in HCC patients is grade 3 and occurs in 1% of those treated with PD-L1 antibodies and 2.6% of those treated with a CTLA-4 antibody and PD-L1 antibody combination [196]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.